Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/113937
DC FieldValueLanguage
dc.contributor.authorSánchez Sosa, José Santiagoen_US
dc.contributor.authorRodriguez-Medina, Cen_US
dc.contributor.authorStuckey, Ren_US
dc.contributor.authorFlorido, Yen_US
dc.contributor.authorSantana, Gen_US
dc.contributor.authorMartin, JMGen_US
dc.contributor.authorCruz-Cruz, Nen_US
dc.contributor.authorTorres-Ochando, Men_US
dc.contributor.authorFernandez, Ren_US
dc.contributor.authorSanchez-Farias, Nen_US
dc.contributor.authorCionfrini, Aen_US
dc.contributor.authorMolero Labarta, María Teresaen_US
dc.contributor.authorGómez Casares, María Teresaen_US
dc.contributor.authorBilbao Sieyro, Cristinaen_US
dc.date.accessioned2022-03-03T12:23:19Z-
dc.date.available2022-03-03T12:23:19Z-
dc.date.issued2022en_US
dc.identifier.issn1837-9664en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/113937-
dc.description.abstractRecent advances in sequencing technologies and genomics have led to the development of several targeted therapies such as BCL2 and Bromodomain and extra-terminal (BET) protein inhibitors for a more personalized treatment of patients with acute myeloid leukemia (AML), yet the majority of patients still receive standard induction chemotherapy. The molecular profiles of patients who are likely to respond to induction therapy and novel directed therapies remain to be determined. The expression of AML-related genes that are targeted by novel therapies such as BCL2 and BRD4, as well as functionally related genes and associated epigenetic modulators (TET2, EZH2, ASXL1, MYC) were analyzed in a series of 176 consecutive AML patients at multiple points during the disease course - diagnosis (Dx), post-induction (PI), complete remission (CR) and relapse (RL) - and their relationship with clinical variables and outcome investigated. Higher TET2 expression was observed PI and at CR compared to Dx, with significantly superior TET2 expression after induction therapy in the group of patients who reached CR compared to those who did not. Thus, the upregulation of TET2 at PI may be a marker of CR in AML patients. On the other hand, cells with high levels of MYC and BCL2 may be vulnerable to BRD4 inhibition.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Canceren_US
dc.sourceJournal of Cancer [ISSN 1837-9664], v. 13 (4), p. 1356-1362 (Enero 2022)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320101 Oncologíaen_US
dc.subject320504 Hematologíaen_US
dc.subject.otherAcute myeloid leukemiaen_US
dc.subject.otherBiomarkersen_US
dc.subject.otherPatient outcomeen_US
dc.subject.otherInduction therapyen_US
dc.subject.otherMolecular diagnosticsen_US
dc.titleCan the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following Induction Therapy?en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typearticleen_US
dc.identifier.doi10.7150/jca.57457en_US
dc.identifier.scopus85127066446-
dc.identifier.isiWOS:000756408300002-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.authorscopusid57216528499-
dc.contributor.authorscopusid55482691500-
dc.contributor.authorscopusid8940351300-
dc.contributor.authorscopusid36953039500-
dc.contributor.authorscopusid56294288100-
dc.contributor.authorscopusid57225067629-
dc.contributor.authorscopusid57225070548-
dc.contributor.authorscopusid57550315700-
dc.contributor.authorscopusid23110607500-
dc.contributor.authorscopusid57551481900-
dc.contributor.authorscopusid57550315800-
dc.contributor.authorscopusid57225068174-
dc.contributor.authorscopusid6602513846-
dc.contributor.authorscopusid57550315900-
dc.identifier.eissn1837-9664-
dc.description.lastpage1362en_US
dc.identifier.issue4-
dc.description.firstpage1356en_US
dc.relation.volume13en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.date.coverdateEnero 2022en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,19-
dc.description.jcr4,207-
dc.description.sjrqQ2-
dc.description.jcrqQ2-
dc.description.scieSCIE-
dc.description.miaricds10,5-
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptDepartamento de Didácticas Específicas-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptDepartamento de Morfología-
crisitem.author.orcid0000-0002-7211-8003-
crisitem.author.orcid0000-0003-0505-5126-
crisitem.author.orcid0000-0002-4796-1445-
crisitem.author.fullNameSánchez Sosa, José Santiago-
crisitem.author.fullNameMolero Labarta, María Teresa-
crisitem.author.fullNameGómez Casares, María Teresa-
crisitem.author.fullNameBilbao Sieyro, Cristina-
Appears in Collections:Artículos
Adobe PDF (552 kB)
Adobe PDF (513,66 kB)
Show simple item record

Page view(s)

36
checked on Jul 16, 2022

Download(s)

5
checked on Jul 16, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.